Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD)
- 31 December 2003
- journal article
- clinical trial
- Published by Elsevier BV in Pulmonary Pharmacology & Therapeutics
- Vol. 16 (6), 341-347
- https://doi.org/10.1016/s1094-5539(03)00090-7
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Phosphodiesterase 4 Inhibitors for the Treatment of COPDSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2002
- Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary diseaseCurrent Opinion in Allergy and Clinical Immunology, 2002
- Cyclic nucleotide phosphodiesterasesJournal of Allergy and Clinical Immunology, 2001
- Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging studyThe Lancet, 2001
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Induced sputum in adolescents with severe stable asthma. Safety and the relationship of cell counts and eosinophil cationic protein to clinical severityEuropean Respiratory Journal, 1999
- Phosphodiesterase IsozymesAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthmaEuropean Respiratory Journal, 1996
- Standardization of Spirometry, 1994 Update. American Thoracic Society.American Journal of Respiratory and Critical Care Medicine, 1995
- Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task ForceEuropean Respiratory Journal, 1995